Monografie
Characterization of bispecific antibodies that drive synthetic agonistic receptor-transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models
- Sprache
-
Englisch
- Identifier
-
1235325873
Thema
Cancer; T cells; Therapeutics; Bispecific antibodies
Beteiligte Personen und Organisationen
Benmebarek, Mohamed-Reda
Kobold, Sebastian
Kobold, Sebastian
- DOI
-
10.5282/edoc.27833
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:52 MEZ
Objekttyp
- Monografie
Beteiligte
- Benmebarek, Mohamed-Reda
- Kobold, Sebastian
Ähnliche Objekte (12)
Combination of C-C chemokine receptor 8 and dominant-negative TGF-β-receptor 2 expression in T cells for adoptive T cell therapy of solid cancer
Nanotools for cancer research and therapy
A patient-specific CT-Mesh hybrid computational phantom and its applications in out-of-field dose, equivalent dose, and secondary cancer risk estimation in proton therapy
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Targeted delivery of magnetic nanocarriers for characterization and therapy in gastro-intestinal cancers
Investigation of Molecular Mechanisms of Therapy Resistance in Lung Cancer by Mathematical Modeling
Cardiotoxicity during checkpoint inhibitor therapy in patients with advanced skin cancer
Combination therapy targeting both innate and adaptive immunity improves survival in a preclinical model of ovarian cancer
Validation of CCR2-targeted mesoporous silica nanoparticles for lung cancer therapy
Inter- and Intrafraction Motion Management for MR guided Proton Therapy of Pancreatic Carcinoma
Novel EGFR family member binding antibodies as cancer therapeutics
STED Nanoscopy to Illuminate New Avenues in Cancer Research – From Live Cell Staining and Direct Imaging to Decisive Preclinical Insights for Diagnosis and Therapy
Combination of C-C chemokine receptor 8 and dominant-negative TGF-β-receptor 2 expression in T cells for adoptive T cell therapy of solid cancer
Nanotools for cancer research and therapy
A patient-specific CT-Mesh hybrid computational phantom and its applications in out-of-field dose, equivalent dose, and secondary cancer risk estimation in proton therapy
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Targeted delivery of magnetic nanocarriers for characterization and therapy in gastro-intestinal cancers
Investigation of Molecular Mechanisms of Therapy Resistance in Lung Cancer by Mathematical Modeling
Cardiotoxicity during checkpoint inhibitor therapy in patients with advanced skin cancer
Combination therapy targeting both innate and adaptive immunity improves survival in a preclinical model of ovarian cancer
Validation of CCR2-targeted mesoporous silica nanoparticles for lung cancer therapy
Inter- and Intrafraction Motion Management for MR guided Proton Therapy of Pancreatic Carcinoma
Novel EGFR family member binding antibodies as cancer therapeutics
STED Nanoscopy to Illuminate New Avenues in Cancer Research – From Live Cell Staining and Direct Imaging to Decisive Preclinical Insights for Diagnosis and Therapy
Combination of C-C chemokine receptor 8 and dominant-negative TGF-β-receptor 2 expression in T cells for adoptive T cell therapy of solid cancer
Nanotools for cancer research and therapy
A patient-specific CT-Mesh hybrid computational phantom and its applications in out-of-field dose, equivalent dose, and secondary cancer risk estimation in proton therapy
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Targeted delivery of magnetic nanocarriers for characterization and therapy in gastro-intestinal cancers
Investigation of Molecular Mechanisms of Therapy Resistance in Lung Cancer by Mathematical Modeling
Cardiotoxicity during checkpoint inhibitor therapy in patients with advanced skin cancer
Combination therapy targeting both innate and adaptive immunity improves survival in a preclinical model of ovarian cancer
Validation of CCR2-targeted mesoporous silica nanoparticles for lung cancer therapy
Inter- and Intrafraction Motion Management for MR guided Proton Therapy of Pancreatic Carcinoma
Novel EGFR family member binding antibodies as cancer therapeutics